The long term objective of this proposal is to develop and identify compounds which are effective in treating AIDS and other HIV- related diseases. The studies described in this proposal will aid in the collaborative efforts of this drug discovery group to develop and identify compounds which specifically inhibit HIV enzymes, either reverse transcriptase (RT), endonuclease, or a protease which is thought to be virus specified.
The specific aims of this laboratory will be to: 1) collaborate to better characterize biochemical events following HIV infection in cultured cells, both T-lymphocytes and monocytes/macrophages; 2) furnish immunoaffinity purified RT to the group; 3) immunoaffinity purify the HIV endonuclease, characterize its substrate and develop an endonuclease assay; 4) evaluate anti RT, endonuclease, and protease compounds for cytotoxicity and anti-HIV activity in cultured cells, both T-lymphocytes and monocytes/macrophage; 5) using HIV infected cultured cells, collaborate with other investigators to determine the mode of action of anti-HIV compounds; 6) study selection of virus resistant to anti-HIV compounds; and 7) study the interaction of new compounds with other current or new compounds in inhibiting HIV in cultured cells.
Showing the most recent 10 out of 21 publications